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Abstract 
Background: The tumor immunosuppressive microenvironment represents a major obstacle to an effective tumor-
specific cellular immune response.
Methods: In the present study, the counterbalance effect of a novel metronomic chemotherapy protocol on such an 
immunosuppressive microenvironment was evaluated in a mouse model upon sub-cutaneous ectopic implantation 
of B16 melanoma cells. The chemotherapy consisted of a novel multi-drug cocktail including taxanes and alkylating 
agents, administered in a daily metronomic fashion. The newly designed strategy was shown to be safe, well tolerated 
and significantly efficacious.
Results: Treated animals showed a remarkable delay in tumor growth and prolonged survival as compared to con-
trol group. Such an effect was directly correlated with CD4+ T cell reduction and CD8+ T cell increase. Furthermore, a 
significant reduction in the percentage of both CD25+FoxP3+ and CD25+CD127low regulatory T cell population was 
found both in the spleens and in the tumor lesions. Finally, the metronomic chemotherapy induced an intrinsic CD8+ 
T cell response specific to B16 naturally expressed Trp2 TAA.
Conclusion: The novel multi-drug daily metronomic chemotherapy evaluated in the present study was very effec-
tive in counterbalancing the immunosuppressive tumor microenvironment. Consequently, the intrinsic anti-tumor 
T cell immunity could exert its function, targeting specific TAA and significantly containing tumor growth. Overall, 
the results show that this represents a promising adjuvant approach to significantly enhance efficacy of intrinsic or 
vaccine-elicited tumor-specific cellular immunity.
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Background
Containment of tumor growth by cellular immunity is 
significantly hampered by intrinsic immunosuppressive 
mechanisms. CD4+CD25+FoxP3+ regulatory T cells 
(Tregs) and myeloid-derived suppressor cells (MDSCs) 
are the main cell types contrasting the effective anti-
tumor cellular immunity.
Tregs represent about 4  % of peripheral CD4+T cells 
in both humans and mice, playing a relevant physiologi-
cal control mechanism on the effector immune response. 
Indeed, they promote peripheral immune tolerance by 
suppressing self-antigen reactive T cells preventing the 
emergence of phathological autoimmune response [1]. 
On the contrary, in cancer patients, high percentage of 
Tregs in peripheral blood as well as in tumor site is asso-
ciated with tumor progression and poor prognosis [2, 3]. 
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reduction of antitumor immunity by suppressing NK and 
T cell responses through various mechanisms, includ-
ing the expression of the inhibitory checkpoint regulator 
cytotoxic T lymphocyte-associated protein 4 (CTLA4) 
on their surface and the production of immunosuppres-
sive mediators such as IL-10 and transforming growth 
factor β1 (TGFβ1) [4–6].
Myeloid-derived suppressor cells (MDSCs) are a het-
erogeneous population of myeloid cells, which sup-
press innate and adaptive antitumor immune response 
by favoring the recruitment and expansion of Tregs, as 
well as by producing high levels of L-arginase, reactive 
oxygen species (ROS), inducible nitrogen oxide syn-
thase (iNOS), and various immunosuppressive cytokines. 
Overall, these enzymes and soluble mediators promote 
neo angiogenesis and allow the escape of immune cells 
from immune surveillance promoting disease progres-
sion [7–10]. Moreover, the accumulation of such MDSCs 
in the peripheral blood and within neoplastic lesions has 
been associated with poor prognosis in a large number of 
cancer patients [11].
Such an intra-tumoral immunosuppressive envi-
ronment is one of the major foundation of the tumor 
escaping the immune mediated control as well as the 
unsatisfactory results observed in cancer immunotherapy 
clinical trials [12–15].
Treatments aiming at limiting these immunosuppres-
sive cell populations should be taken into consideration 
in order to restore antitumor immune responses and 
improve cancer vaccine efficacy [16].
Low-dose or metronomic chemotherapeutic regimens 
have been shown to selectively kill immunosuppressive 
cell populations. This would eventually result in dramatic 
improvement in both the intrinsic immune containment 
of tumor growth and the immune response elicited by 
immunotherapy strategies.
Conventional chemotherapeutic agents were devel-
oped for their capacity to directly kill malignant cells at 
a maximal tolerated dose (MTD), the highest amount of 
the drug associated with tolerable toxicity. More recently, 
alternative schedules of treatment have been proposed 
and evaluated for such agents. Repetitive administra-
tion of chemotherapeutics at low dosage (so-called, met-
ronomic chemotherapy) has been shown to induce an 
antiangiogenic activity associated with strong anti-neo-
plastic effects in absence of toxicity (reviewed in [17]). 
Additionally, low dose of metronomic chemotherapy 
have been shown to promote the expression of MHC 
class I molecules on the surface of cancer cells, facilitat-
ing their antigen-dependent killing mediated by CD8+ 
cytotoxic T cells (CTL) [18]. Moreover, metronomic 
chemotherapy induce in cancer cells an “immunogenic 
death”resulting in release of immunostimulatory factors 
(reviewed in [19]).
Chemotherapeutics can convert the tumor micro-
environment into a site permissive for vaccination by 
enhancement of antigen density and accumulation of 
dendritic cells [20]. Moreover, pretreatment with met-
ronomic chemotherapy can enhance the immunization 
efficacy by promoting the maturation and activation of 
dendritic cells (DCs) in vitro, in turn stimulating the pro-
liferation of CD4 and CD8 T cells along with an increased 
production of interferon γ (IFN-γ) [18].
In this framework, it has been shown that metro-
nomic chemotherapy with cyclophosphamide (CTX) or 
paclitaxel (PTX) in single or daily administration may 
significantly reduce the number of regulatory T cells 
[3, 21]. Such an effect results in improved T cell–medi-
ated antitumor responses in both preclinical and clini-
cal studies [22, 23] as well as improved immunogenicity 
of vaccines [24–26]. A combination of CTX, PTX and 
doxorubicin has been previously shown to enhance the 
immune response to vaccine when administered in a sin-
gle administration schedule (i.e. 1  day before or 7  days 
after vaccination) [27]. Docetaxel (DTX) has been previ-
ously shown to increase antigen-specific T cell responses 
when combined to a vaccine with a schedule different 
from daily [28].
In this perspective, the overall objective of this study 
was to evaluate the immunomodulatory effects of a 
novel multi drugs metronomic chemotherapy in an 
aggressive therapeutic setting based on sub-cutaneous 
ectopic implantation of B16 melanoma cells. In particu-
lar, the metronomic chemotherapy included a multi-
drug cocktail including taxanes (DTX and PTX) and 
alkylating (CTX) agents, aiming at hitting different tar-
gets of the immune suppressive tumor microenviron-
ment [29].
The newly designed strategy in the present study was 
shown to be safe, well tolerated and significantly effica-
cious in both delaying tumor growth and prolonging ani-
mal survival. Such anti-tumor biological effects directly 
correlated with reduction of the immune suppressive 
Tregs cell population.
These results are highly promising for an effec-
tive counterbalancing of the intra-tumor suppressive 
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micro-environment and pave way to new adjuvant strategies 
to significantly improve immunotherapeutic treatments.
Methods
Cell line and mice
C57BL/6 (H-2b MHC) female mice, 8  week old, were 
purchased from Harlan (Udine, Italy). All animals were 
housed at the Animal Facility of the Istituto Nazionale 
Tumori “Pascale” (Naples, Italy). Mice were maintained 
under specific pathogen-free conditions, and all proce-
dures were in accordance with recommendations for the 
proper use and care of laboratory animals.
Mouse melanoma B16F10 (ATCC, CRL-6323) cells 
were cultured in DMEM supplemented with 10  % heat 
inactivated FBS, 100  U/ml penicillin and 100  mg/ml 
streptomycin (Invitrogen, Carlsbad, CA) at 37  °C with 
5 % CO2. Cells were tested for mycoplasma before inocu-
lation in mice.
Antibodies for flow cytometry
Rabbit polyclonal antibody against calreticulin (PA3-
900) was purchased from ThermoFisher (Rockford, IL, 
USA). Alexa Fluor 488 goat anti-rabbit IgG (A11008) 
was purchased from Life Technology (Eugene, OR, 
USA). PE-conjugated anti-mouse CD4 (clone RM4-
5),PE/Cy7-conjugated anti-mouse CD8 (clone 53-6.7), 
FITC-conjugated anti-mouse CD25 (clone 3C7), Alexa 
Fluor 488-conjugated anti-mouseFoxP3 (clone 150D), 
APC-conjugated anti-mouse Gr-1 (clone RB6-8C5) and 
FITC-conjugated anti-mouse CD11b (clone M1/70) 
antibodies were purchased from BioLegend (San Diego, 
CA). PerCP-eFluor 710-conjugated anti-mouse CD3 
(clone 17-A2)and APC eFluor 780-conjugatedanti-mouse 
CD127 (clone A7R34) antibodies were purchased from 
eBioscience (San Diego, CA).
Chemotherapy administration
Cyclophosphamide (CTX) (10  mg/Kg), PTX (5  mg/Kg) 
and DTX (1  mg/Kg) diluted with phosphate-buffered 
saline (PBS) were administered via intraperitoneal injec-
tion (i.p.).The dose was extrapolated to human equiva-
lent dose (HED) according to Reagan-Shaw et  al. [30]. 
Chemotherapy was daily administered until the end of 
the experiment.
In vitro cytotoxic effect
Mouse melanoma B16F10 cells were cultured for 12, 24 
and 48 h at a concentration of 5 × 105 cells per well in a 
6-well plate in the presence of different concentrations 
of CTX, PTX and DTX. Drugs were added indepen-
dently or as cocktail at indicated doses. Cells were col-
lected, washed in PBS, pelleted and resuspened in 500 µl 
of PBS. Cell death was assessed by propidium iodide 
staining at flow cytometry using FACScan hardware 
using CellQuest software (BD Biosciences, Mountain 
View, CA).
Calreticulin expression on the cell surface
Mouse melanoma B16F10 cells were cultured for 4 h at 
a concentration of 5 × 105 cells per well in a 6-well plate 
in the presence of different concentrations of CTX, PTX 
and DTX. Drugs were added independently or as cock-
tail at indicated doses. Cells were collected, washed twice 
with PBS and fixed in 0.25 % of paraformaldehyde in PBS 
for 5 min. After washing again twice with cold PBS, cells 
were incubated for 30  min with anti-calreticulin (CRT) 
primary antibody diluted in cold blocking buffer (2 % FBS 
in PBS), followed by washing and incubation with the 
Alexa 488-conjugated monoclonal secondary antibody 
for 30 min. Each sample was analyzed by flow cytometry 
using FACScan hardware using CellQuest software (BD 
Biosciences, Mountain View, CA). Expression of CRT 
was evaluated on cell surface of propidium iodide nega-
tive cells. Untreated B16F10 melanoma cells were used as 
negative control.
Subcutaneous tumor inoculation
Melanoma B16 cells were harvested in exponential 
growth phase by trypsinization and washed twice with 
ice-cold PBS, and then resuspended at a concentration 
of 1 × 106 cells/ml. C57BL/6 mice were subcutaneously 
injected with 100 ul of B16 cells (1 × 105 cells/mouse) on 
the right back flank. The tumor size was measured and 
documented every 3 days with a caliper, starting on day 
7, and calculated using the formula (A × B2)/2 (A as the 
largest and B is the smallest diameter of tumor). Tumor 
growth was documented as mean tumor size with stand-
ard error disregarding single distant outliers. To record 
the survival of the tumor-bearing mice, either natural 
death or a tumor volume greater than 1600 mm3 leading 
to death was counted as death. Each experimental group 
included five animals.
Characterization of regulatory T lymphocytes in whole 
blood, in spleens and in tumors
For Tregs detection whole blood samples of each mouse 
was directly staining with PE-conjugated anti-mouse 
CD4 and FITC-conjugated anti-mouse CD25 and 
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incubated for 30  min at 4  °C. Following staining, whole 
blood was incubated with ACK lysing buffer for 7  min, 
washed with wash Medium (1  ×  PBS, 5  % FBS, 0.1  % 
NaN3), and after permeabilization, incubated with Alexa 
Fluor 488-conjugated anti-mouseFoxP3 for 30  min at 
4  °C in the dark. The blood samples were collected and 
Tregs evaluated before mouse euthanasia.
After dissociation, splenocytes and tumor cells were 
incubated with ACK lysing buffer for 7 min, washed and 
resuspended in RPMI medium and incubated for 30 min 
at 4  °C in the dark with PE-conjugated anti-mouse CD4 
and FITC-conjugated anti-mouse CD25 and APC eFluor 
780-conjugatedanti-mouse CD127. After washing and 
permeabilization, cells were incubated with Alexa Fluor 
488-conjugated anti-mouseFoxP3 for 30  min at 4  °C in 
the dark. To detect CD11b+/Gr-1+ myeloid-derived 
suppressor cells (MDSCs) from mouse splenocytes and 
single tumor cell preparations, cells were stained with 
APC-conjugated anti-mouse Gr-1 and FITC-conjugated 
anti-mouse CD11b antibodies.
The staining was characterized by flow cytometry using 
FACScan hardware using CellQuest software (BD Bio-
sciences, Mountain View, CA).
IFN‑γ ELISpot assay
ELISPOT was performed according to BD Biosciences 
manufacturer instructions(BD ELISPOT Mouse IFN-γ 
ELISPOT Set cod. 551083). 2.5 ×  105 splenocytes were 
counted and plated in each well in duplicate. Cells were 
stimulated with 2 ug/ml of Trp2 peptide as well as with 
5  ug/ml of phorbol myristate acetate (PMA, Sigma-
Aldrich) and incubated for 24–26 h. As negative control 
PBS was used. The plates were read with an AID EliSpot 
Reader Systems (AID GmbH, Strassberg, Germany). The 
results were calculated as spot forming counts as a mean 
of a duplicate count from the specific antigen stimulation 
minus the negative control.
Statistical analysis
Comparison between individual data points were per-
formed with the unpaired two-sided Student’s t test. All 
P values were two-tailed and considered significant if less 
than 0.05.
Results
Cytotoxic effects in vitro of chemotherapy drugs
Cytotoxic effects of CTX, DTX and PTX was assessed 
in vitro on B16F10 melanoma cells. Drugs were added to 
cell culture independently or as cocktail, in concentra-
tions ranging from 1 to 100 µM. After incubation for 12, 
24 and 48  h, cell death was assessed by flow cytometer 
cell counting, using the vital dye propidium iodide (PI). 
Results indicated that the three drugs induced a dose and 
time-dependent cell death, with different efficacy. Indeed, 
PTX and DTX showed a more pronounced cytotoxic 
effect than CTX. Moreover, the mix of the drugs induced 
a cumulative effect, mainly at lower doses and earlier 
time points (Fig. 1). Kinetic and morphological analyses 
indicated that morphologically discernible apoptosis was 
followed by secondary necrosis (data not shown).
Calreticulin expression as marker of immunogenic cell 
death
In order to assess whether CTX, PTX, DTX induced an 
immunogenic cell death, CRT expression was evaluated 
on the cell surface of B16F10 melanoma cells by flow 
Fig. 1 Mouse melanoma B16F10 cells were cultured for 12, 24 and 48 h at a concentration of 5 × 105 cells per well in a 6-well plate in the presence 
of indicated concentrations of CTX, PTX, DTX and their mix. Cell death was assessed by propidium iodide staining at flow cytometry
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cytometer after short-term stimulation (4  h). Results 
showed that the three drugs induced different levels of 
CRT expression on the surface of PI-negative cells. PTX 
and DTX induced a higher CRT expression than CTX. 
Moreover, the mix of the drugs induced a cumulative 
effect (Fig. 2). Interestingly, all drugs, alone or in the mix, 
induced the strongest effect at 10 µM concentration, with 
a significant reduction at 100 uM (Fig. 2).
Effect of daily multi‑drug metronomic chemotherapy 
on tumor growth and mice survival
In accordance to the in  vitro results, a new multi-drug 
combination including CTX, DTX and PTX was designed 
to investigate its effect on tumor growth in vivo. C57BL/6 
mice (five animals per group) were subcutaneously 
injected with B16F10 cells and daily treated in a low-dose 
metronomic fashion (Fig. 3).
The general status of animals in the experimental 
groups was followed up during the whole protocol. No 
toxicity was observed, all animals showing good gen-
eral status without any significant weight loss during the 
whole treatment.
After injection of B16 tumor cells, animals were mon-
itored every 3  days for tumor growth. Mice were sacri-
ficed when tumor volume reached 1600 mm3 according 
to ethical rules.
The results showed that the metronomic chemotherapy 
significantly delays tumor growth as compared to the con-
trol group. At day 19, when all animals in both experimen-
tal groups were still alive and comparable, mice treated with 
Fig. 2 Mouse melanoma B16F10 cells were cultured for 4 h at a concentration of 5 × 105 cells per well in a 6-well plate in the presence of indicated 
concentrations of CTX, PTX, DTX and their mix. Expression of CRT was evaluated on cell surface of propidium iodide negative cells. Values indicate 
the percentage of increase over the untreated B16F10 control cells
Fig. 3 C57BL/6 mice were injected with 1 × 105 cells in the right flank. The experimental group was treated daily in a metronomic fashion with a 
cocktail containing CTX (10 mg/Kg), PTX (5 mg/Kg) and DTX (1 mg/Kg)
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metronomic chemotherapy showed a 70  % reduction in 
tumor dimension. Furthermore, even at the end of experi-
ment, when all mice had to be sacrificed for ethical rules, 
the metronomic chemotherapy group showed tumor lesions 
with dimensions 30 % smaller than control group (Fig. 4a).
Consequently, the Kaplan-Meyer curve shows that, on 
average, the experimental group treated with daily met-
ronomic chemotherapy had a significant prolonged sur-
vival (Fig. 4b).
Effects of daily metronomic chemotherapy on T cell 
populations
Immunological analyses were performed on PBMCs, 
resected spleens and tumors from mice of both experi-
mental groups.
Daily metronomic chemotherapy induced a reduction 
in the CD4+ T cells which was significant in PBMCS as 
well as in tumors, and a trend in the spleens. In parallel, 
CD8+ T cells significantly increased in PBMCs as well 
as in spleens, without significant change in the tumor 
(Fig. 5a, b). Nevertheless, the CD4+/CD8+ ratio did not 
drop below 1 which is the normal ratio in C57BL/6 mice 
at this age [31]. Such ratio is considered as marker of an 
immune competence status in HIV positive patients [32] 
(data not shown).
Daily Metronomic chemotherapy reduces Treg population
In order to clarify the immunological mechanisms under-
lying the observed delay in tumor growth observed in the 
animal group treated with the daily metronomic chemo-
therapy, Tregs were evaluated in PBMCs, the spleen and 
the tumor microenvironment.
The results showed a significant reduction in 
CD4+CD25+FoxP3+ as well as CD4+CD25+CD127low 
Treg populations in both spleens and tumors of mice 
treated with daily metronomic chemotherapy as com-
pared to untreated groups. On the contrary, Tregs were 
not reduced but even increased in PBMCs in treated ani-
mals as compared to control group (Fig. 6a and b).
In order to verify whether the percentage of intra-
splenic and/or intra-tumor Tregs population correlated 
with tumor growth and survival, a correlation analysis 
was performed. Results showed a strong inverse corre-
lation between percentage of intra-splenic and/or intra-
tumor Tregs population with tumor growth and survival. 
Indeed, the lowest percentage of Tregs was observed in 
mice showing the slowest tumor growth and the longest 
survival (p < 0.035) (Figs. 7, 8).
Evaluation of IFN‑γ producing T cells
Splenocytes were further assessed for IFN-γ production 
in an Elispot assay. Upon re-stimulation with tumor-
associated Trp2 peptide, only splenocytes from mice 
treated with metronomic chemotherapy showed a signifi-
cant IFN-γ production (Fig.  9). Interestingly, this group 
showed also a relatively high IFN-γ production at base-
line as well as upon PMA stimulation, suggesting a gen-
eral T cell activation induced by the chemotherapy.
A direct correlation between levels of IFN-γ production 
and survival was observed (p  <  0.023), to confirm that 
such responsive T cells play a key role in the observed 
delay of tumor growth and increased animal survival.
Conclusion
In the current study, the immunomodulatory effect of a 
daily administered novel multi-drug metronomic chemo-
therapy was evaluated in a tumor bearing mouse model.
In particular, the metronomic chemotherapy consisted 
of a multi-drug cocktail including taxanes (docetaxel 
Fig. 4 a Tumor growth was evaluated every three days with a caliper 
and tumor volume was calculated as indicated in Materials and Meth-
ods. Animals were sacrificed when tumor volume was greater than 
1600 mm3. b Kaplan-Meyer curve showing the percentage of survival 
of animals in both experimental groups
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and paclitaxel) and alkylating (cyclophosphamide) 
agents, to hit different targets of the immune suppressive 
environment.
The results of ex  vivo treatment of B16F10 cells with 
drugs showed that they have different cell toxicity and 
properties in inducing an immunological cell death. 
This represents the required effect in order to provide 
immunogenic signals and induce an effective anti-tumor 
immunity. In particular, the taxanes showed the most 
potent activity. Moreover, the drug mix significantly 
potentiated the individual activities, supporting the use 
in the in vivo animal experiments.
The combined metronomic chemotherapy was admin-
istered in a daily schedule in C57BL/6 animal model 
injected with the highly aggressive B16F10 melanoma cell 
line.
The treatment induced a significant reduction in tumor 
growth and prolonged survival as compared to the con-
trol group (Fig.  2a, b). Such effect was directly corre-
lated with reduction of CD4+ Tcells and parallel increase 
of CD8+ Tcells (Fig.  3). CD4+CD25+FoxP3+as well as 
CD4+CD25+CD127low Treg populations were found sig-
nificantly reduced in both spleens and tumors of sacri-
ficed mice treated with daily metronomic chemotherapy 
as compared to untreated groups (Fig. 4). The percentage 
of intra-splenic and/or intra-tumor Treg populations, 
and not in PBMCs, showed a strong inverse correla-
tion with tumor growth and survival. Indeed, the lowest 
percentage of Tregs was observed in mice showing the 
slowest tumor growth and the longest survival (Figs.  5, 
6). Such findings indicating that the effects of daily met-
ronomic chemotherapy was directly correlated with a 
Fig. 5 Evaluation of CD4+ and CD8+ T cells in PBMCs spleens and tumors in both experimental groups expressed as absolute numbers (a) and 
percentages (b). In PBMCs T0 represents the percentage at beginning of the protocol; T1 represents the percentage at the end of the protocol
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sustained reduction in the Treg population in spleens and 
in the tumor, as previously reported [3, 21, 26, 33–40].
Unlike the observed reduction in spleens and 
tumors, Tregs level in PBMCs of treated animals 
were similar or even higher as compared to untreated 
groups. Such a discrepancy has been reported also by 
others [41]. This could be explained by the observa-
tion that the lymphocyte recovery after the lympho-
penia induced by chemotherapy results in increased 
Treg proliferation [42]. Indeed, Tregs show a higher 
regeneration rate compared to Teffs (8  days vs, 
24–199 days) [43]. This would allow Tregs to return to 
their normal cell cycling and growth in the germinal 
centers and their rapid re-enter in circulation. Over-
all, such a finding confirms that evaluation of circu-
lating Trges is not representative of the intratumoral 
microenvironment.
IFN-γ producing T cells were found to be significantly 
higher in splenocytes of treated animals as compared to 
control group (Fig. 7). Such result was observed not only 
upon ex vivo re-stimulation with tumor-associated Trp2 
peptide but also at baseline as well as upon PMA stimula-
tion. Also for this parameter, a direct correlation between 
levels of IFN-γ production and survival was observed, to 
confirm that such responsive T cells play a key role in the 
observed in vivo effects.
Fig. 6 Evaluation of CD4+ CD25+FoxP3+ and CD4+ CD25+CD127low T regulatory cells in PBMCs, spleens and in the tumor of animals in both 
experimental groups expressed as absolute numbers (a) and percentages (b)
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The described results suggest that the chemotherapy 
exerts a two-pronged activity, both inducing an “immu-
nological death” of cancer cells and a general T cell acti-
vation, resulting in delayed tumor growth and increased 
survival.
Overall, these results provide a rationale for the use of 
the novel multi-drug chemotherapeutic combination to 
overcome the immunesuppressive tumor microenviron-
ment. Such effect would eventually result in dramatic 
improvement in the intrinsic immune containment 
Fig. 7 Correlation analysis between day of sacrifice of each animal and percentage of CD4+ CD25+FoxP3+ T regulatory cells in PBMCs, spleens and 
in the tumor
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of tumor growth as well as the immune response elic-
ited by immunotherapy strategies. To this aim, a com-
binatorial strategy including the described multi-drug 
metronomic chemotherapy and cancer vaccines will 
provide further experimental evidences to confirm such 
observation.
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